DEF: Heron Therapeutics Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals
Proxy Statement
Heron Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 12, 2025, featuring proposals for director elections, auditor ratification, and executive compensation.
Summary
- Heron Therapeutics will hold its 2025 Annual Meeting of Stockholders on June 12, 2025, at 9:00 a.m. Eastern Time, conducted exclusively via remote communication.
- Stockholders of record as of April 15, 2025, are entitled to vote at the meeting.
- The meeting will address the election of six director nominees, ratification of Withum Smith+Brown, PC as the independent accounting firm, and advisory votes on executive compensation and the frequency of future compensation votes.
- Stockholders can attend, vote, and submit questions online at www.virtualshareholdermeeting.com/HRTX2025, using a 16-digit control number.
- The Board recommends voting for all director nominees, for the ratification of Withum, for the approval of executive compensation, and for holding advisory votes on executive compensation every one year.
Sentiment
Score: 7
Explanation: The document is neutral in tone, providing necessary information for the upcoming shareholder meeting. It outlines standard corporate governance procedures and proposals, suggesting a stable and organized approach to company management.
Positives
- The Board recommends voting for all director nominees, for the ratification of Withum, for the approval of executive compensation, and for holding advisory votes on executive compensation every one year.
- The meeting will be accessible online, allowing for broader stockholder participation.
Future Outlook
The company expects the next advisory Say-on-Pay vote will occur at the 2026 Annual Meeting and the next Say-on-Pay frequency vote will occur at the 2031 annual meeting of stockholders.
Industry Context
This announcement is typical for publicly traded companies as they prepare for their annual meetings, ensuring compliance with SEC regulations and providing shareholders with the opportunity to participate in key decisions.
Comparison to Industry Standards
- The director compensation program is compared to a peer group of 17 companies including Aeri Pharmaceuticals, Intercept Pharmaceuticals, Albireo Pharma, Karyopharm Therapeutics, Coherus BioSciences, Ocular Therapeutics, Collegium Pharmaceuticals, OptiNose, Deciphera Pharmaceuticals, Rigel Pharmaceuticals, Eagle Pharmaceuticals, Vanda Pharmaceuticals, Esperion Therapeutics, Vericel, Eyepoint Pharmaceuticals, Xeris Biopharma Holdings and G 1 Therapeutics.
- The peer group includes companies with marketed pharmaceutical products across a wide variety of disease states.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Operating Officer | NA | Mark Hensley | 2025-04 | New appointment |
| Director | Susan Rodriguez | NA | 2025-06-12 | Not standing for re-election |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Committee Composition | Susan Rodriguez is not standing for re-election at the Annual Meeting and currently serves on the Compensation and Nominating and Corporate Governance Committees of the Board. | 2025-06-12 | Potentially requires adjustments to committee membership and leadership. |
| Cash Compensation | Increased the 2025 cash retainer for the Lead Independent Director to align with market norms. | 2025 | Aligns director compensation with market standards. |
Related Party Transactions
- There were no related person transactions since January 1, 2024 that require disclosure under Item 404 of Regulation S-K.
Stakeholder Impact
- Shareholders have the opportunity to vote on key company matters, influencing the direction and governance of Heron Therapeutics.
- Executive officers are subject to a clawback policy, ensuring accountability for financial reporting accuracy.
- Employees are provided with an Employee Stock Purchase Plan, offering increased equity ownership opportunities.
Next Steps
- Stockholders are encouraged to vote on the proposals before the Annual Meeting.
- The company will file a Current Report on Form 8-K to publish the final voting results within four business days after the Annual Meeting.
Key Dates
| Date | Description |
|---|---|
| 2021-08 | Withum acquired certain assets of OUM & Co. LLP, Heron's independent registered accounting firm from 2006 through August 2021. |
| 2023-02-21 | Date of Cooperation Agreement between the Company, Rubric Capital Management LP, and Velan Capital Investment Management LP. |
| 2023-10-02 | Date from which incentive compensation is subject to the clawback policy. |
| 2024-12-31 | End of fiscal year for which executive compensation is being reviewed. |
| 2025-04-15 | Record Date for determining stockholders eligible to vote at the Annual Meeting. |
| 2025-04-30 | Mailing date of the Notice of Internet Availability of Proxy Materials. |
| 2025-06-11 | Deadline for submitting proxies via the Internet or telephone (11:59 p.m. Eastern Time). |
| 2025-06-12 | Date of the 2025 Annual Meeting of Stockholders at 9:00 a.m. Eastern Time. |
| 2025-12-30 | Deadline for stockholders to submit proposals for inclusion in the 2026 Proxy Statement. |
| 2026-02-12 | Earliest date for stockholders to deliver written notice of director nominations or other business proposals for the 2026 Annual Meeting. |
| 2026-03-14 | Latest date for stockholders to deliver written notice of director nominations or other business proposals for the 2026 Annual Meeting. |
| 2026-04-13 | Deadline for shareholders to provide notice with information required by Rule 14a-19 under the Exchange Act. |
Keywords
Annual Meeting, Proxy Statement, Stockholders, Director Election, Executive Compensation, Auditor Ratification, Corporate Governance, Heron Therapeutics
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.